Perioperative exposure to lipopolysaccharide (LPS) is associated with accelerated metastatic colorectal tumour growth. LPS directly affects cells through Toll-like receptor 4 (TLR-4) and the transcription factor NF-κB. The urokinase plasminogen activator (u-PA) system is intimately implicated in tumour cell extracellular matrix (ECM) interactions fundamental to tumour progression. Thus we sought to determine if LPS directly induces accelerated tumour cell ECM adhesion and invasion through activation of the u-PA system and to elucidate the cellular pathways involved. Human colorectal tumour cell lines were stimulated with LPS. u-PA concentration, u-PA activity, active u-PA, surface urokinase plasminogen activator receptor (u-PAR) and TLR-4 expression were assessed by ELISA, colorimetric assay, western blot analysis and flow cytometry respectively. In vitro tumour cell vitronectin adhesion and ECM invasion were analysed by vitronectin adhesion assay and ECM invasion chambers. u-PA and u-PAR function was inhibited with anti u-PA antibodies or the selective u-PA inhibitors amiloride or WXC-340, TLR-4 by TLR-4-blocking antibodies and NF-κB by the selective NF-κB inhibitor SN-50. LPS upregulates u-PA and u-PAR in a dose-dependent manner, enhancing in vitro tumour cell vitronectin adhesion and ECM invasion by >40% (P<0.01). These effects were ameliorated by u-PA and u-PAR inhibition. LPS activates NF-κB through TLR-4. TLR-4 and NF-κB inhibition ameliorated LPS-enhanced u-PA and u-PAR expression, tumour cell vitronectin adhesion and ECM invasion. LPS promotes tumour cell ECM adhesion and invasion through activation of the u-PA system in a TLR-4- and NF-κB-dependent manner.
Surgery remains the only definitive curative modality for colorectal cancer (Meyerhardt and Mayer, 2005). Unfortunately, the perioperative milieu may facilitate the progression of previously dormant occult metastatic disease (Da Costa et al, 1998). Although the mechanisms underlying this phenomenon are not fully elucidated, implicated factors include perioperative immune suppression (Li et al, 2001), elevated angiogenic and inflammatory cytokine levels (Da Costa et al, 1998) and elimination of putative tumour-suppressing agents with primary tumour excision (Coussens and Werb, 2002).
Lipopolysaccharide (LPS) or endotoxin, the foremost glycolipid outer membrane constituent of Gram-negative bacteria, potently stimulates immune system cells by binding cell-surface Toll-like receptor 4 (TLR-4) and activating transcription factors and protein kinases, such as NF-κB and p38 kinase, resulting in an increased production of pro-inflammatory cytokines, overexpression of cell adhesion molecules and matrix-degrading enzymes (Manthey et al, 1992). Contemporary studies have demonstrated the expression of TLR-4 on human colorectal cancer cells and highlighted a key function for the TLR system in the development of colitis-associated tumours, suggesting a role for this receptor in colorectal cancer development and progression (Böcker et al, 2003; Fukata et al, 2007).
LPS has recently been implicated in accelerated metastatic tumour growth after surgery. Following laparotomy and air laparoscopy, LPS contaminates the peritoneal cavity and enters the systemic circulation due to perioperative bacterial gut translocation. In murine metastatic breast carcinoma models, mice undergoing laparotomy or air laparoscopy had increased serum levels of LPS and metastatic tumour burden compared to those in the CO2 laparoscopy group, a result replicated by intraperitoneal LPS injection (Pidgeon et al, 1999; Harmey et al, 2002). This association between LPS and accelerated perioperative tumour growth may be a manifestation of a direct effect on cancer cells or a circuitous immunologically mediated singularity. Luo et al (2004) suggest that endotoxin is subservient to inflammatory cytokines produced primarily by the innate immune system, as the LPS-induced enhanced tumour burden was TNF-α dependant and abolished in TLR4-deficient mice.
Although it has been extensively demonstrated that bacterial endotoxin (LPS), analysed in both in vitro and in vivo experimental settings, reduces apoptosis (Andrews et al, 2001; Wang et al, 2003) and increases proliferation in metastatic tumour cells (Coffey et al, 2006), the role of extracellular matrix (ECM)-degrading enzyme systems remains to be elucidated in this phenomenon.
For a tumour to become invasive and ultimately metastasise, tumour cells must cross cellular and matrix boundaries by attaching to, interacting with, and invading components of the basement membrane and ECM, culminating in access to the circulation (Hart and Saini, 1992; Al-Mehdi et al, 2000). Comprising several interdependent components, the urokinase plasminogen activator (u-PA) system has a number of distinct but complementary functions in this tightly regulated multi-step process. The serine protease u-PA is secreted as a 55 kDa proenzyme proteolytically cleaved to an enzymatically active two-chain form (Pollanen et al, 1988; Sidenius and Blasi, 2003). Its 60 kDa glycosylphosphatidylinositol-linked receptor, urokinase plasminogen activator receptor (u-PAR/CD87), binds the epidermal growth factor-like domain of active u-PA (Vassalli et al, 1985; Pollanen et al, 1990) and the ECM constituent vitronectin (Roldan et al, 1990; Waltz and Chapman, 1994). Plasminogen activator inhibitors 1 (PAI-1; Kanse et al, 1996) and PAI-2 form trimeric complexes with u-PAR bound u-PA, culminating in internalisation, u-PA/PAI degradation and u-PAR recycling (Declerck et al, 1988). u-PA/u-PAR promotes cell/cell and cell/ECM proteolysis by regulating localised plasminogen activation (Cubellis et al, 1990). Independent of proteolysis, u-PA enhances cell invasion through activation of several migration-associated signalling molecules such as extracellular signal-regulated kinases (Nguyen et al, 1998), focal adhesion kinases (Tang et al, 1998) and signal transducers and activators of transcription 1 (STAT1) (Dumler et al, 1998). Such intercellular signal transduction is apparently facilitated by the interaction of u-PAR with integrins (Wei et al, 1996; Degryse et al, 2001) and cytoskeletal components (Xue et al, 1997). In addition, u-PA/u-PAR mediates cellular adhesion to the ECM protein, vitronectin directly through integrin-independent, high-affinity interaction between u-PAR and vitronectin, and indirectly through function modifying lateral associations with integrin family members (Xue et al, 1997; Degryse et al, 2001).
A number of experimental and clinical studies highlight the significance of the u-PA system in colorectal cancer abound (Ertongur et al, 2004; Setyono-Han et al, 2005). Both Harvey et al (1999) and Skelly et al (1997) demonstrated superior 5-year survival rates in patients whose tumour had lower total u-PA expression after curative colon cancer resection. Herszényi et al (2008) showed elevated serum levels of u-PA in patients with colorectal cancer. A high u-PAR concentration in resected colorectal cancers is an independent and significant prognostic factor for 5-year overall survival (Ganesh et al, 1994). It has also been demonstrated that a serum protein fraction representing soluble u-PAR (su-PAR: u-PAR protein without the glycolipid anchor) is inversely correlated with survival (Stephens et al, 1999). Suzuki et al (1998) showed that u-PAR expression increases during the transition from adenoma to invasive carcinoma in colorectal epithelium.
Despite being implicated in promoting colon cancer progression, the effect of LPS on u-PA and u-PAR expression, and the function of this system in endotoxin augmented colon cancer cell invasiveness, is not known. The aim of this study, therefore, was to determine if the u-PA system is involved in endotoxin-enhanced tumour cell adhesion and extracellular invasion, and to elucidate the function of TLR-4 and NF-κB in this process.
Materials and methods
Reagents and antibodies (Abs)
Medium L-15, DMEM, HBSS, PBS without Ca2+ and Mg2+, fetal calf serum (FCS), penicillin, streptomycin sulphate, glutamine and 0.05% trypsin/0.02% EDTA solution were purchased from Invitrogen Life Technologies (Paisley, Scotland, UK). Human vitronectin, LPS (Escherichia coli O55B5), and all other chemicals unless indicated were from Sigma-Aldrich (St Louis, MO, USA). Human u-PA, the cell-permeable NF-κB inhibitor peptide, SN-50 and its non-functioning control analogue SN-50M were obtained from Calbiochem (San Diego, CA, USA). Monoclonal anti-u-PA and anti-u-PAR Abs were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-TLR-4-blocking mAb (clone, HTA-125), FITC-conjugated anti-TLR-4 mAb and isotype-control Abs were from eBioscience (San Diego, CA, USA) and Serotec (Oxford, UK) respectively. Anti-u-PAR (CD87) mAb and its isotype-control mAb were from R&D systems (Minneapolis, MN, USA). Horseradish-peroxidase-conjugated secondary mAbs were purchased from Dako (Cambridgeshire, UK). The novel u-PA inhibitor, WXC-340, was kindly donated by Dr Bernd Muehlenweg (Wilex AG, Munich, Germany).
Human colorectal tumour cell lines SW480, SW620 and CACO2 were obtained from American Type Culture Collection (Manassas, VA, USA). SW480 and SW620 cells were grown in medium L-15 whereas CACO2 cells were cultured in DMEM. Culture medium was supplemented with 10% FCS, penicillin (100 U ml−1), streptomycin sulphate (100 μg ml−1) and glutamine (2.0 mM). Cells were maintained at 37°C in a humidified 5% CO2 atmosphere and subcultured by trypsinisation with 0.05% trypsin/0.02% EDTA when cells became confluent. All studies were performed within 10 passages of obtaining the cell lines.
Cell stimulation and sample preparation
Cells cultured in six-well plates (1 × 106 cells per well; Falcon, Lincoln Park, NJ, USA) were exposed to various concentrations of LPS (0.1, 1 and 10 μg ml−1) for different time periods (0, 6, 12, 18 and 24 h) at 37°C in humidified 5% CO2 conditions. Cell-free supernatants were collected by centrifugation at 400 g for 10 min and frozen at −70°C or analysed immediately. To assess the function of protein synthesis in LPS-enhanced u-PA and u-PAR expression, cells were co-incubated with various concentrations of cycloheximide (Paisley, UK).
Western blot analysis for TLR-4 involved unstimulated cell lysates. To examine the role of TLR-4 and NF-κB in LPS-enhanced u-PA and u-PAR expression, cells were incubated with various concentrations of TLR-4-blocking Ab and SN-50, respectively, before LPS stimulation. In dose–response experiments the optimal inhibitory concentration was determined and used in all subsequent experiments (25 and 100 μg ml−1 respectively). CACO2 cells were cultured with 1 mM butyrate for 24 h as a positive control as described by Gibson et al (1999).
For western blot analysis of cell supernatant u-PA, conditioned medium was concentrated 90- to 100-fold using centricon 10 centrifugal filter units (Millipore, Bedford, MA, USA) with a 10 kDa pore diameter cutoff. Protein concentrations were determined using a Micro BCA protein assay reagent kit (Pierce, Rockford, IL, USA). Cell homogenate total protein samples were mixed loading buffer (60 mM Tris, 2.5% SDS, 10% glycerol, 5% mercaptoethanol, 0.01% bromophenol blue) in a 1 : 1 ratio whereas concentrated conditioned medium for cell supernatant u-PA western blot analysis was mixed with sample buffer 3 : 1 ratio. Samples were denatured for 10 min at 100°C.
u-PA and u-PAR ELISA
Levels of u-PA and PAI-1 in culture supernatants and cell homogenates, and u-PAR in cell homogenates, were measured using commercially available u-PA and u-PAR ELISA kits (American Diagnostica, Greenwich, CT, USA) according to the manufacturer's instruction.
UPA activity assay
The urokinase plasminogen activator activity levels in cell supernatants were measured using a commercially available chromogenic u-PA activity assay kit (Chemicon, Temecula, CA, USA). Values are expressed as IU per mg protein.
Western blot analysis
Aliquots containing equal amount of total proteins from each sample were separated in SDS-polyacrylamide gels and electrophoretically transferred onto nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany). Membranes were blocked for 1 h at room temperature with PBS containing 0.05% Tween 20 and 5% non-fat milk, and probed overnight at 4°C with primary Abs at conditions recommended by the manufacturers. Blots were washed three times with PBS containing 0.05% Tween 20 and 5% non-fat milk and further incubated with the appropriate horseradish-peroxidase-conjugated secondary Ab at room temperature for 1 h. Immunoreactive proteins visualised using the ECL detection system (Amersham Biosciences, Piscataway, NJ, USA). To ensure equal protein loading, all membranes were stripped and re-probed with anti-β-actin Ab where indicated. Western blot analysis studies were performed in duplicate and repeated on three separate occasions.
Measurement of NF-κB activation
SW480, SW620 and CACO2 cells were incubated with 0.1 μg ml−1 LPS for 30 min. Briefly, cells were lysed in a hypotonic solution (10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl and 0.1% Nonidet P-40, pH 7.9) on ice for 10 min and centrifuged at 13 000 r.p.m. to pellet nuclei. Cytoplasmic supernatants were removed, and nuclei were re-suspended in nuclear extract buffer (20 mM HEPES, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2 and 0.2 mM EDTA, pH 8.0) on ice for 15 min. The lysates were centrifuged at 13 000 r.p.m., and supernatants containing the nuclear proteins were collected. All buffers contained freshly added 0.5 mM DTT, 0.5 mM PMSF and protease inhibitor cocktail (Roche, Mannheim, Germany). Protein concentrations were determined using a Micro BCA protein assay reagent kit (Pierce). All extracts were stored at −70°C until analysed. NF-κB activation was measured by the NF-κB ELISA kit (Active Motif, Carlsbad, CA, USA) according to the manufacturer's recommendations.
Cells were exposed to various concentrations of LPS (0.1, 1 and 10 μg ml−1) for different time periods (0, 6, 12, 18 and 24 h) at 37°C in humidified 5% CO2. The expression of u-PAR and TLR-4 on SW480, SW620 and CACO2 cells was determined using direct immunofluorescent staining. Briefly, 20 μl of FITC-conjugated anti-u-PAR or FITC-conjugated anti-TLR-4 mAbs was added to 100 μl of cell suspension (1 × 106 cells per ml) and incubated at 4°C for 30 min. FITC-conjugated isotype IgG1 mAbs were used as negative controls. Cell-surface expression of u-PAR and TLR-4 was analysed on a FACScan flow cytometer (BD Biosciences, Mountain View, CA, USA) to detect the log of the mean channel fluorescence intensity with an acquisition of FL1. A minimum of 10 000 events were collected and analysed on CellQuest software (BD Biosciences).
Tumour cell vitronectin adhesion assay
Human vitronectin (1 μg ml−1), poly-Lysine (1 μg ml−1) and BSA (1 μg ml−1, used as a negative control) were coated onto 96-well, flat-bottom plates (Falcon). SW480, SW620 and CACO2 cells were exposed to various concentrations of LPS (0.1, 1 and 10 μg ml−1) for different time periods (0, 6, 12, 18 and 24 h) at 37°C in humidified 5% CO2 conditions. For blocking experiments, cells were pre-treated with various concentrations of SN-50 (100 μg ml−1), SN-50M (100 μg ml−1), u-PA inhibitors (10 mg ml−1 amiloride, 0.3 mg ml−1 WXC-340), u-PA (20 μg ml−1), u-PAR (20 μg ml−1) and TLR-4-blocking Abs (25 μg ml−1) for 1 h before LPS stimulation. The above cell suspension (100 μl; 1 × 106 cells per ml) was added in triplicate to the vitronectin-, poly-Lysine- and BSA-coated 96-well plates and incubated for 2 h at 37°C in humidified 5% CO2 conditions. The cell suspension was discarded and the remaining adherent cells were washed twice with PBS. Fluorescent probe precursor (100 μl), calcein-AM (Calbiochem) was added to each well. Fluorescence was measured using a fluorescence plate reader at an excitation wavelength of 485 nm and emission wavelength of 520 nm. Standard curves to convert measured fluorescence to cell number were constructed utilising known cell numbers.
Tumour cell invasion assay
In vitro tumour cell invasion was assessed using an ECM in vitro ECM invasion chambers (Chemicon) with cell culture inserts containing an 8μm pore size positron emission tomography membrane with a thin layer of ECM membrane matrix as previously described. Briefly, 0.5 ml of tumour cells (1 × 105 cells per ml) re-suspended in serum-free medium containing various concentrations of LPS (0.1, 1 or 10 μg ml−1) was added to the cell culture insert of the invasion chamber. FBS (20 μg ml−1) was added in the outer chamber as a chemoattractant. SW480 and SW620 cells were pretreated with various concentrations of SN-50 (100 μg ml−1), SN-50M (100 μg ml−1), u-PA inhibitors (10 mg ml−1 amiloride, 0.3 mg ml−1 WXC-340), u-PA (20 μg ml−1), u-PAR (20 μg ml−1) and TLR-4-blocking Abs (25 μg ml−1) for 1 h before LPS stimulation. The cells were then incubated at 37°C in humidified 5% CO2 conditions for 24 h. Invaded cells that attached to the bottom of the matrix membrane were detached and lysed in cell lysis buffer. Cell lysates were then stained with CyQuant-GR-Dye (Chemicon). Fluorescence was measured using a fluorescence plate reader at an excitation wavelength of 485 nm and emission wavelength of 520 nm. A standard curve to convert measured fluorescence to cell number was constructed using known cell numbers.
All data are presented as the mean±s.d. Student's two-tailed t-test was used to compare data between two groups. One-way analysis of variance and Bonferroni's correction were used to compare data between three or more groups. Differences were judged statistically significant at P<0.05.
LPS enhances u-PA release and activity in colon cancer cells
Stimulation of SW480 and SW620 tumour cells with LPS increased u-PA protein release in a dose-dependent manner. LPS at 0.1 μg ml−1 was sufficient to enhance u-PA levels in the cell supernatants (Figure 1A). This occurred within 12 h of LPS stimulation (Figure 1B). LPS stimulation induced increased u-PA activity in both SW480 and SW620 cell supernatants (Figure 1C). This was mirrored by increased expression of activated two-chain u-PA in SW480 and SW620 cells following LPS stimulation on western blot analysis of concentrated cell supernatants (Figure 1D). Nevertheless, LPS-stimulated upregulation of u-PA activity was almost completely blocked by two u-PA selective antagonists, amiloride and WXC-340 (Figure 1C). Metastatic SW620 cells had higher baseline u-PA protein and activity levels than primary SW480 cells (Figure 1A and C).
LPS enhances u-PAR expression in colon cancer cells
SW480, SW620 and CACO2 tumour cells constitutively expressed cell-surface u-PAR as confirmed by FACScan analysis (Figure 2A). Baseline total cellular u-PAR levels were significantly higher in primary SW480 cells than in metastatic SW620 cells (Figure 2B). LPS increased total cellular and surface u-PAR levels in a dose-dependent manner (Figure 2B and C).
LPS increases tumour cell adhesion and invasion
Different constitutive adhesion to the ECM protein vitronectin and in vitro invasion through ECM were observed between naive SW480 and SW620 cells (Figure 3A and B). Non-specific poly-D-lysine binding was similar in both cell lines and for LPS-stimulated and unstimulated cells (data not shown). LPS significantly increased tumour cell vitronectin adhesion (Figure 3A). Both cell lines demonstrated a significant 38% increase in vitronectin adhesion when stimulated with 0.1 μg ml−1 LPS (P<0.05 compared to cells treated with culture medium alone). In vitro tumour cell invasion was also enhanced by approximately 43% in SW480 and SW620 cells treated with 0.1 μg ml−1 LPS versus culture medium alone (P<0.05; Figure 3B).
Inhibition of u-PAR and u-PA attenuates LPS-mediated tumour cell adhesion and invasion
SW480 and SW620 cells pre-incubated with the u-PAR function-blocking mAb for 1 h before LPS stimulation failed to demonstrate enhanced vitronectin adhesion (P<0.05 compared to cells treated with LPS or LPS plus isotype mAb control) (Figure 4A). Pre-treatment with either u-PA (20 μg ml−1) or u-PAR (20 μg ml−1) function-blocking mAbs or the selective u-PA inhibitors, amiloride (10 mg ml−1) and WXC-340 (0.3 mg ml−1) partially impaired LPS-enhanced tumour cell invasion (P<0.05 compared to cells treated with LPS or LPS plus isotype mAb control) (Figure 4B and C). Combined u-PA and u-PAR inhibition further impaired both basal and LPS-stimulated tumour cell invasion in an additive manner (P<0.05 compared to cells treated with LPS or LPS plus u-PA, u-PAR or isotype-control mAb alone) (Figure 4B and C).
SW480 and SW620 cells express TLR-4 whereas TLR-4 inhibition attenuates LPS-mediated activation of the u-PA and u-PAR system, tumour cell adhesion and invasion
Both SW480 and SW620 cells showed low constitutive expression of TLR-4 on the cell surface whereas CACO2 cells lacked TLR-4 surface expression, as confirmed by FACScan analysis (Figure 5A). CACO2 cells failed to demonstrate increased u-PA or u-PAR expression after stimulation with varying concentrations of LPS but did when stimulated with butyrate (Figure 5B and C). Pre-treatment of SW480 and SW620 cells with a TLR-4-blocking Ab (25 μg ml−1 HTA-125) for 1 h before LPS stimulation significantly reduced both u-PA and u-PAR expression and u-PA activity (P<0.05 compared to cells stimulated with LPS alone or LPS plus isotype Ab control) (Figure 5B and C). CACO2 cells failed to demonstrate increased tumour cell vitronectin adhesion (Figure 5D) and in vitro tumour cell invasion (Figure 5E) in response to LPS stimulation. TLR-4 blockade also significantly reduced LPS-dependent tumour cell vitronectin adhesion (Figure 5D) and in vitro tumour cell invasion for SW480 and SW620 cell lines (Figure 5E).
LPS increases NF-κB activation whereas NF-κB inhibition attenuates LPS-mediated activation of the u-PA and u-PAR system, tumour cell adhesion and invasion
Stimulation of SW480 and SW620 cells with 0.1 μg ml−1 LPS for 30 min increases NF-κB activity. This LPS-enhanced NF-κB activity is attenuated by TLR-4 inhibition (Figure 6A). SN-50 is a cell-permeable peptide containing a hydrophobic N-terminal linked to the nuclear localisation sequence of NF-κB p50, which prevents nuclear translocation of LPS and TNF-α-activated NF-κB. SN-50M has two-peptide substitution and no measurable effect on NF-κB activation in LPS-stimulated cells. Pre-treatment of SW480 and SW620 cells with 100 μg ml−1 of SN-50, for 1 h before LPS stimulation, inhibited LPS-induced upregulation of u-PA activity (Figure 6B) and u-PAR expression (Figure 6C) compared to cells stimulated with LPS (P<0.05) or LPS plus SN-50M (P<0.05). Furthermore, SN-50 pre-treatment attenuated LPS-dependent tumour cell vitronectin adhesion (Figure 6D) and in vitro ECM invasion (Figure 6E) compared to cells stimulated with LPS (P<0.05) or LPS plus SN-50M (P<0.05).
Protein synthesis inhibition impairs LPS-mediated activation of the u-PA and u-PAR system
Cycloheximide is a protein synthesis inhibitor that inhibits the initiation of new peptide chains and the elongation of nascent peptides on ribosomes by different mechanisms (Ennis and Lubin, 1964).
Co-incubation of SW480 and SW620 cells with 10 μg ml−1 of cycloheximide inhibited LPS-induced upregulation of u-PA (Figure 7A), u- PA activity (Figure 7B), total (Figure 7C) and surface u-PAR expression (Figure 7D) compared to cells stimulated with LPS alone (P<0.05). Furthermore cycloheximide attenuated LPS-dependent tumour cell vitronectin adhesion (Figure 7E) and in vitro ECM invasion (Figure 7F) compared to cells stimulated with LPS alone (P<0.05). This suggests that the stimulatory effect of LPS is at least partially mediated at the transcriptional level.
Bacterial endotoxin directly and indirectly facilitates cancer progression in vitro and in vivo through a multitude of complimentary mechanisms. Fundamental to this process is tumour cell invasion involving cell attachment to the subendothelial ECM and subsequent unidirectional cell migration coupled with local proteolysis induced by a number of enzymes, particularly MMPs and u-PA (Pollanen et al, 1988; Sidenius and Blasi, 2003). We have previously demonstrated that LPS enhances tumour cell invasion in colorectal tumour cells through a mechanism at least partially mediated by NF-κB-dependent β1 integrin upregulation (Wang et al, 2003). However invasion is ultimately subservient in many cases to local pericellular proteolysis. SW480 and SW620 express low levels of MMPs, which were unaltered with LPS stimulation (data not shown). Therefore this study focused on the contribution of another proteolytic cascade, the u-PA system, to endotoxin-mediated accelerated tumour invasion.
The SW480 cell line was cultured from a primary rectal tumour and the SW620 cell line from a secondary hepatic metastases derived from the same patient. Interestingly, basal u-PA and u-PA activity levels were approximately 40% higher in metastatic SW620 cells compared to primary SW480 cells. This was mirrored in higher basal levels of in vitro invasion using the ECM invasion chamber. In contrast, baseline surface and total cellular expression of u-PAR was higher in SW480 cells when compared to SW620 cells, and therefore, adhesion to its specific ligand vitronectin was correspondingly higher in SW480 cells. Although both increased u-PA and u-PAR levels are associated with tumour metastases (Duffy, 2002), elevated u-PA expression may be important in development of the metastatic process in this cell system as acquisition of the metastatic phenotype appears to involve overexpression of u-PA and downregulation of u-PAR. Notwithstanding the differences in basal expression, the relative increase in u-PA protein concentration and activity, and u-PAR surface and total cellular expression with LPS stimulation were similar between both SW480 and SW620 cell lines. Tumour cell vitronectin adhesion and in vitro ECM invasion were likewise consistently amplified with LPS challenge.
Baseline and LPS-associated in vitro cellular invasion was partially repressed by u-PA and u-PAR inhibition. The selective u-PA inhibitor amiloride and novel chemotherapeutic compound WXC-340 also incompletely reduced LPS-enhanced invasion. This reduction occurred to the same extent in both SW480 and SW620 cells. Combined u-PAR and u-PA inhibition further impaired invasion in an additive manner. Such findings incriminate the u-PA system as a pre-eminent end effector mechanism in LPS-mediated enhanced tumour invasion. Constituents of this system could justifiably be targeted in the perioperative period. Indeed, the precursor of WXC-340, wx-uk1 has completed phase I trials in patients with metastatic solid tumours tumours (http://clinicaltrials.gov/ct2/results?term=wx-uk1).
LPS signalling involves TLR-4, a member of the highly conserved family of TLR proteins (Schumann et al, 1990; Perera et al, 2001). Both SW480 and SW620 cells express low but measurable surface levels of TLR-4 whereas CACO2 do not, reflecting the poor response of this cell line to LPS stimulation. Furthermore, LPS-mediated u-PA and u-PAR upregulation and enhanced tumour cell adhesion and invasion was abrogated by TLR-4 blockade using a functional TLR-4-blocking mAb.
On stimulation of TLR-4 with LPS, IκB-α is phosphorylated by IκB-α kinase and thus phosphor-IκB-α is transiently expressed in the cytoplasm concomitant with a similarly transient decrease in cytoplasmic IκB-α (Aggarwal, 2004). In this study blockade of NF-κB activation by SN-50, a synthetic peptide that impedes NF-κB signalling by inhibition of nuclear translocation of NF-κB, abrogated LPS-induced upregulation of the u-PA system and attenuated tumour cell adhesion and invasion, indicating that NF-κB activation is a prerequisite not only for the transduction of LPS signals in tumour cells, but also for the enhanced tumour cell metastatic ability induced by LPS stimulation. Protein synthesis seems fundamental to this LPS-induced upregulation of the u-PA system and enhanced tumour cell adhesion and invasion (Figure 7A–F).
LPS antagonism is another potential perioperative therapy, particularly attractive as it would not impair putatively important TLR-4 or NF-κB function in normal tissue.
Thus stimulation of tumour cell TLR-4 and subsequent NF-κB activation by systemic exposure to LPS in the perioperative period may accentuate tumour cell adhesion and invasion by a variety of mechanisms including activation of the u-PA and integrin systems.
In conclusion, bacterial endotoxin directly promotes tumour cell adhesion and invasion through the upregulation of u-PA and u-PAR mediated by TLR-4-dependent activation of NF-κB (Figure 8). These findings provide further evidence for the involvement of bacterial products in surgery-associated accelerated growth in metastatic disease and justify either selective or collective targeting of LPS, TLR-4 and the u-PA system in the perioperative period to attenuate surgery-induced accelerated metastatic tumour growth.
Aggarwal B (2004) Nuclear factor-κB: the enemy within. Cancer Cell 6: 203–208
Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ (2000) Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med 1: 100–110
Andrews EJ, Wang JH, Winter DC, Lang WE, Redmond HP (2001) Tumor cell adhesion to endothelial cells is increased by endotoxin via an upregulation of beta-1 integrin expression. J Surg Res 97: 14–19
Böcker U, Yezerskyy O, Feick P, Manigold T, Panja A, Kalina U, Herweck F, Rossol S, Singer MV (2003) Responsiveness of intestinal epithelial cell lines to lipopolysaccharide is correlated with Toll-like receptor 4 but not Toll-like receptor 2 or CD14 expression. Int J Colorectal Dis 18: 25–32
Coffey JC, Wang JH, Bouchier-Hayes D, Cotter TG, Redmond HP (2006) The targeting of phosphoinositide-3 kinase attenuates pulmonary metastatic tumor growth following laparotomy. Ann Surg 243 (2): 250–256
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860–866
Cubellis MV, Wun TC, Blasi F (1990) Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9: 1079–1085
Da Costa ML, Redmond HP, Boucher-Hayes DJ (1998) The effect of laparotomy and laparoscopy on the establishment of spontaneous tumour metastases. Surgery 124: 516–526
Declerck PJ, De Mol M, Alessi MC, Baudner S, Paques EP, Preissner KT, Muller Berghaus G, Collen D (1988) Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 263: 15454–15461
Degryse B, Orlando S, Resnati M, Rabbani SA, Blasi F (2001) Urokinase/urokinase receptor and vitronectin/alpha (v)-beta (3) integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways. Oncogene 20: 2032–2043
Duffy MJ (2002) Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 48: 1194–1197
Dumler I, Weis A, Mayboroda OA, Maasch C, Jerke U, Haller H, Gulba DC (1998) The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J Biol Chem 273: 315–321
Ennis HL, Lubin M (1964) Cycloheximide: aspects of inhibition of protein synthesis in mammalian cells. Science 146: 1474–1476
Ertongur S, Lang S, Mack B, Wosikowski K, Muehlenweg B, Gires O (2004) Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer 110: 815–824
Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, Subbaramaiah K, Cooper HS, Itzkowitz SH, Abreu MT (2007) Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133: 1869–1881
Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB, Verspaget HW (1994) Urokinase receptor and colorectal cancer survival. Lancet 344: 401–402
Gibson PR, Rosella O, Wilson AJ, Mariadason JM, Rickard K, Byron K, Barkla DH (1999) Colonic epithelial cell activation and the paradoxical effects of butyrate. Carcinogenesis 20: 539–544
Harmey JH, Bucana CD, Lui W, Byrne AM, McDonnell S, Lynch C, Bouchar-Hayes D, Dong Z (2002) Lipopolysaccharide induced metastatic growth is associated with increased angiogenesis, vascular permenability and tumour cell invasion. Int J Cancer 101: 415–422
Hart IR, Saini A (1992) Biology of tumor metastasis. Lancet 339: 1453–1457
Harvey SR, Sait SN, Xu Y, Bailey JL, Penetrante RM, Markus G (1999) Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization. Am J Pathol 155: 1115–1120
Herszényi L, István G, Cardin R, De Paoli M, Plebani M, Tulassay Z, Farinati F (2008) Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers. Eur J Cancer Prev 17 (5): 438–445
Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT (1996) The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 224: 344–353
Li TS, Kaneda Y, Ueda K (2001) The influence of tumour resection on angiostatin levels and tumour growth – an experimental study on tumour bearing mice. Eur J Cancer 37: 2283–2288
Luo JL, Maeda S, Hsu LC, Yagita H, Karin M (2004) Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNF-alpha to TRAIL-mediated tumor regression. Cancer Cell 6: 297–305
Manthey CL, Brandes ME, Perera PY, Vogel SN (1992) Taxol increases steady-state levels of lipopolysaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages. J Immunol 149 (7): 2459–2465
Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352: 476–487
Nguyen DH, Hussaini IM, Gonias SL (1998) Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 273: 8502–8507
Perera PY, Mayadas TN, Takeuchi O, Akira S, Zaks-Zilberman M, Goyert SM, Vogel SN (2001) CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression. J Immunol 166: 574–579
Pidgeon GP, Harmey JH, Kay E, Da Costa M, Redmond HP, Bouchier-Hayes DJ (1999) The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer 81: 1311–1317
Pollanen J, Stephens R, Salonen EM, Vaheri A (1988) Proteolytic mechanisms operating at the surface of invasive cells. Adv Exp Med Biol 233: 187–199
Pollanen J, Vaheri A, Tapiovaara H, Riley E, Bertram K, Woodrow G, Stephens RW (1990) Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class-2 plasminogen activator inhibitor. Proc Natl Acad Sci USA 87: 2230–2234
Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Danø K, Appella E, Blasi F (1990) Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9: 467–474
Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ (1990) Structure and function of lipopolysaccharide binding protein. Science 249: 1429–1434
Setyono-Han B, Sturzebecher J, Schmalix WA, Muehlenweg B, Sieuwerts AM, Timmermans M, Magdolen V, Schmitt M, Klijn JG, Foekens JA (2005) Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb Haemost 93: 779–786
Sidenius N, Blasi F (2003) The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22: 205–222
Skelly MM, Troy A, Duffy MJ, Mulcahy HE, Duggan C, Connell TG, O'Donoghue DP, Sheahan K (1997) Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin Cancer Res 3: 1837–1840
Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sørensen S, Danø K, Brünner N (1999) Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 91: 869–874
Suzuki S, Hayashi Y, Wang Y, Nakamura T, Morita Y, Kawasaki K, Ohta K, Aoyama N, Kim SR, Itoh H, Kuroda Y, Doe WF (1998) Urokinase type plasminogen activator receptor expression in colorectal neoplasms. Gut 43: 798–805
Tang H, Kerins DM, Hao Q, Inagami T, Vaughan DE (1998) The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem 273: 18268–18272
Vassalli JD, Baccino D, Belin D (1985) A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100: 86–92
Waltz DA, Chapman HA (1994) Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 269: 14746–14750
Wang JH, Manning BJ, Wu QD, Blankson S, Bouchier-Hayes D, Redmond HP (2003) Endotoxin/lipopolysaccharide activates NF-kappaB and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism. J Immunol 170: 795–804
Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA (1996) Regulation of integrin function by the urokinase receptor. Science 273: 1551–1555
Xue W, Mizukami I, Todd III RF, Petty HR (1997) Urokinase type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res 57: 1682–1689
About this article
Cite this article
Killeen, S., Wang, J., Andrews, E. et al. Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-κB-dependent activation of the urokinase plasminogen activator system. Br J Cancer 100, 1589–1602 (2009). https://doi.org/10.1038/sj.bjc.6604942
- perioperative metastatic tumour growth
- extracellular matrix
- urokinase plasminogen activator system
- Toll-like receptor 4
Current Colorectal Cancer Reports (2019)
Trapping of Lipopolysaccharide to Promote Immunotherapy against Colorectal Cancer and Attenuate Liver Metastasis
Advanced Materials (2018)
Drug Resistance Updates (2018)
Applied Microbiology and Biotechnology (2018)
Basic understanding and therapeutic approaches to target toll-like receptors in cancerous microenvironment and metastasis
Medicinal Research Reviews (2018)